These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. Qian G; Yao W; Zhang S; Bajpai R; Hall WD; Shanmugam M; Lonial S; Sun SY Cancer Lett; 2018 Oct; 435():44-54. PubMed ID: 30059709 [TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma. Vandross A Semin Oncol; 2017 Dec; 44(6):381-384. PubMed ID: 29935899 [TBL] [Abstract][Full Text] [Related]
31. Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series. Richter J; Biran N; Duma N; Vesole DH; Siegel D Hematol Oncol; 2017 Jun; 35(2):246-251. PubMed ID: 27018162 [TBL] [Abstract][Full Text] [Related]
32. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956 [TBL] [Abstract][Full Text] [Related]
33. Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy. Scott GB; Carter C; Parrish C; Wood PM; Cook G Cell Immunol; 2015 Sep; 297(1):1-9. PubMed ID: 26051632 [TBL] [Abstract][Full Text] [Related]
34. [Synergistic effect and mechanism of baicalein in combination with lenalidomide-induced apoptosis of myeloma cells]. Zhang RB; He L; Huang Z; Ma Z; Liu SQ Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):546-7. PubMed ID: 23827119 [No Abstract] [Full Text] [Related]
35. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938 [TBL] [Abstract][Full Text] [Related]
36. Lenalidomide mode of action: linking bench and clinical findings. Davies F; Baz R Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Gay F; Mina R; Troia R; Bringhen S Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1517-27. PubMed ID: 23961770 [TBL] [Abstract][Full Text] [Related]
38. [Carfilzomib in multiple myeloma relapses]. Bay JO Bull Cancer; 2015 Feb; 102(2):116. PubMed ID: 25874287 [No Abstract] [Full Text] [Related]
39. Multiple myeloma: new uses for available agents, excitement for the future. Anderson KC J Natl Compr Canc Netw; 2015 May; 13(5 Suppl):694-6. PubMed ID: 25995433 [TBL] [Abstract][Full Text] [Related]
40. Lenalidomide in the treatment of multiple myeloma: a review. Armoiry X; Aulagner G; Facon T J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]